The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Bodes well for next week, but can we see a bit of blue by close.
Good to hear. A few of us have been doing the same.
Abcam?
Any more clues?
I am here...and quietly and regularly adding....
gla
Looks like just you and me gtc - when it pops we will be happy.
New investors or people reducing averages?
Window of opportunity here - next RNS are only going to bring good news and we should be moving up.
Anyone submitted questions in advance of presentation?
&-)
Anyone considering adding ahead of presentation
He does look happy in that interview and with an increased pr presence you have to wonder if something good is happening behind the scenes.
Lol donโt be clueso care to elaborate ๐
If you look close enough. Relationship with former company is the clue.
We will soon enough, I think we are on the cusp of something big
Why are we not ๐ ing?
https://www.linkedin.com/posts/walbrook-pr_fusion-antibodies-reports-second-half-rebound-activity-7193616844224634880-mwuS?utm_source=share&utm_medium=member_ios
Wow typical the great weather is after the bank holiday. Anyone doing anything fun.
Veterinary medicine. Closing beneficial negotiations.
Come on fab letโs see some upward action
@Robdog67, is making a fair point about the state of the AIM per sae and some of these penny share plays. The poster makes a valid point frankly. Some clearly do abuse the trust and support the SH community gives them. Do not diss a posters comments because you don't agree. Put forward your counter argument. The community here is to discuss opportunity pros and cons not just act as an echo chamber.
I await with interest next weeks presentation here, the delivery so far has been pitiful, doing extensive development work for token fees also undervalues them which is not great. I am interested why they did that. Good luck
Robdog67,
What has that got to do with FAB? Have you posted this anywhere else or just here? WHY?
By the way as they were not listed on AIM (they were standard listed on the Main Market of LSE), then most of your post is pointless.
It was also a pre-revenue company that had burnt through ยฃ20m in 4 years, thye were struggling to raise any more cash through the listing.
Wonder what price they would offer for it. Most shareholders in a lot higher
The CEO stated work with the large US biotech partner is progressing well. Down the road any commercial product will lead to meaningful royalties to FAB.
Likewise potential licensing income from collaborating with US Cancer Institute may be company making.
The market cap. Of this cutting edge science outfit would clearly be many, many times greater if listed in the US.
This is a poor reflection on the London stock markets and investing community.
It would be no surprise if FAB is simply snapped up by a foreign listed competitor.
OCTP going off AIM. I can see a lot of these shxty little companies doing the same thing. They should be made to buy out the PI's at a premium, then they wouldn't do it. Can't see why anyone would risk investing their hard earned money in AIM company anymore. They just keep on getting shafting the small investor.